Previous 10 | Next 10 |
Glenview Capital takes new stakes in CCC Intelligent Solutions (NYSE:CCCS) with 2.41M shares, Willis Towers Watson (NASDAQ:WLTW) with 833K shares, and Organon (NYSE:OGN) with 753K shares. Exits Walgreens Boots Alliance (NASDAQ:WBA), Quantum-Si (NASDAQ:QSI), and Medtronic (NYSE:MDT). Boosts st...
Organon was formed via the spin-out of Merck's Women's Health, Biosimilars and Established Brands divisions - shares began trading in May. On Nov. 11, the company reported Q321 earnings, affirming FY21 guidance for $6.2-$6.3bn. Based on nine-month performance, Organon ought to be ...
Organon & Co. (OGN) Q3 Earnings Conference Call November 11, 2021, 8:30 AM ET Company Participants Kevin Ali – Chief Executive Officer Jennifer Halchak – Vice President, Investor Relations Matt Walsh – Chief Financial Officer Conference Call Participants Chris Schott ...
The following slide deck was published by Organon & Co. in conjunction with their 2021 Q3 earnings call. For further details see: Organon & Co. 2021 Q3 - Results - Earnings Call Presentation
Organon (NYSE:OGN) is trading flat in the pre-market after the company reported Q3 2021 financials exceeding analyst expectations. Merck spinoff focused on women’s health and biosimilars also narrowed its full-year guidance. For the quarter, the topline dipped ~1% YoY to $1.6B aft...
Organon (NYSE:OGN) declares $0.28/share quarterly dividend, in line with previous. Forward yield 3.06% Payable Dec. 16; for shareholders of record Nov. 22; ex-div Nov. 19. See OGN Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Organon declares $0.28 div...
Organon (NYSE:OGN): Q3 Non-GAAP EPS of $1.67 beats by $0.23; GAAP EPS of $1.27 beats by $0.07. Revenue of $1.6B (-0.6% Y/Y) beats by $10M. Press Release For further details see: Organon EPS beats by $0.23, beats on revenue
Third quarter 2021 revenue of $1,600 million Net income from continuing operations of $323 million, or $1.27 per diluted share; Adjusted net income from continuing operations of $424 million, or $1.67 per diluted share Adjusted EBITDA of $636 million Board of Dir...
Acquisition adds pipeline of candidates targeting novel treatments in women’s health Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug de...
Organon (NYSE:OGN) is scheduled to announce Q3 earnings results on Thursday, November 11th, before market open. The consensus EPS Estimate is $1.44 and the consensus Revenue Estimate is $1.59B. Organon shares traded ~4% higher after the company swung back to growth with better than&...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 16:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
VANCOUVER, BC / ACCESSWIRE / July 31, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce a new significant gold-silver discovery, called the Navidad vein system, on the Ermitaño Mine concessions in Sonora, Mexico where the Company holds a...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...